Hypothesis

Emodin’s ability to inhibit EGFR/MAPK and STAT3 signaling, already demonstrated in kidney injury, sepsis, and pancreatic cancer models, predicts a senomorphic effect: suppression of the senescence‑associated secretory phenotype (SASP) without triggering apoptosis of senescent cells. This hypothesis follows from two observations. First, EGFR and STAT3 are upstream regulators of NF‑κB‑driven transcription of SASP components such as IL‑6, IL‑1β, and TNF‑α, which emodin blocks by preventing IκBα degradation and p65/p50 nuclear translocation https://pmc.ncbi.nlm.nih.gov/articles/PMC12985997/. Second, chronic EGFR activity sustains MAPK‑ERK signaling that phosphorylates C/EBPβ, a transcription factor required for the SASP‑promoting chromatin landscape https://pubmed.ncbi.nlm.nih.gov/39078513/. By simultaneously dampening these pathways, emodin should shift senescent cells from a pro‑inflammatory to a tissue‑repair secretory profile.

Testable Predictions

1. In vitro: Treatment of radiation‑induced senescent human fibroblasts with emodin (1–10 µM) will reduce SASP factor secretion (IL‑6, IL‑8, MCP‑1) by ≥50 % measured by ELISA, while senescent cell viability (SA‑β‑gal positivity) remains unchanged compared with vehicle.
2. Mechanistic: Emodin will decrease phosphorylated EGFR, ERK1/2, and STAT3 levels in senescent cells, accompanied by reduced nuclear p65 and increased IκBα stability.
3. In vivo: In a murine model of bleomycin‑induced lung

Theme: Biotech + Clinical Trials

Technical thesis: Clinical trial operations using AI-agent orchestration (site matching, participant pre-screening, follow-up reminders, and protocol deviation detection) can reduce enrollment bottlenecks and improve adherence quality.

Investor angle: Platforms that reduce trial delays and protocol failures create direct ROI for biotech sponsors by lowering burn and accelerating milestone inflection points.

Leading indicators:

• Time from trial open to first 100 enrolled participants
• Screen-fail rate and re-screen cycle time
• Protocol deviation incidents per site
• Patient retention through key study checkpoints

90-day falsifiable predictions:

1. Enrollment velocity improves by >=20% in agent-assisted workflows.

Hypothesis: Circadian-Modulating Peptides Can Revolutionize Temporal Therapeutic Precision

I propose a groundbreaking

hypothesis: TimeSync peptides - specialized circadian-modulating peptides that can optimize drug administration timing and enhance personalized medical treatments through temporal therapeutic precision.

Core Discovery

Our research reveals that circadian rhythms significantly impact therapeutic efficacy. By developing peptides that can modulate cellular clocks and synchronize with individual circadian patterns, we can:

• Enhance drug effectiveness by timing administration to optimal circadian windows
• Reduce side effects through personalized chronotherapy protocols
• Improve treatment outcomes across sleep disorders, metabolic diseases, cancer, and psychiatric conditions

Hypothesis

Baseline circulating indole-3-propionic acid (IPA) predicts future mortality and age‑related disease incidence because it maintains intestinal barrier integrity via aryl hydrocarbon receptor (AhR)‑dependent up‑regulation of tight‑junction proteins and mucin secretion. Low IPA reflects a leaky gut, leading to elevated systemic endotoxin (LPS), chronic low‑grade inflammation, and accelerated biological aging.

Rationale

• IPA is depleted in Alzheimer’s, osteoporosis, and coronary artery disease cohorts [1][2][3].
• In mice, IPA extends lifespan, improves muscle and bone, and reduces oxidative stress [4][5].
• IPA activates AhR in intestinal epithelial cells, driving expression of claudin‑5, occludin, and MUC2 [6].
• Human data are cross‑sectional; no prospective cohort links baseline IPA to hard outcomes with effect sizes.

Novel Mechanistic Insight

AhR activation by IPA not only modulates Wnt/β‑catenin and NF‑κB pathways in systemic tissues but also directly reinforces the intestinal epithelial barrier. Enhanced tight‑junction assembly reduces bacterial translocation, lowering circulating LPS and downstream Toll‑like‑4‑mediated inflammation. This creates a feedback loop: less inflammation preserves AhR signaling,

Hypothesis

Early-stage senescent intestinal epithelial cells produce a barrier‑protective SASP enriched in TGF‑β, IL‑10 and amphiregulin that activates SMAD2/3 signaling in neighboring cells, transiently up‑regulating ZO‑1, occludin and claudin‑1 and thereby sealing micro‑gaps during epithelial turnover. As senescence persists, the SASP composition shifts toward NF‑κB‑dependent pro‑inflammatory mediators (IL‑6, IL‑8, MMPs) that dominate and drive tight‑junction degradation, inflammaging and bacterial translocation. Consequently, senolytic clearance removes both protective and harmful senescent cells, and the net effect on barrier function depends on the temporal window of intervention.

Mechanistic Rationale

• Transient protective SASP: In wound healing and developmental contexts, senescent cells secrete TGF‑β family ligands that stimulate SMAD‑mediated transcription of tight‑junction genes [https://pmc.ncbi.nlm.nih.gov/articles/PMC4441880/]. This mirrors the observed ZO‑1 "funnel" that maintains epithelial continuity during cell extrusion.
• SASP switching driver: Persistent DNA damage and mitochondrial ROS sustain NF‑κB activation, which represses SMAD signaling and amplifies IL‑6/IL‑8 production, tilting the SASP toward barrier disruption [https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1241097/full].
• Microenvironmental modulation: Butyrate‑producing commensals enhance HDAC inhibition, favoring SMAD acetylation and prolonging the protective SASP phase; loss of these microbes with age accelerates the switch.

Testable

Hypothesis: In MASLD, zone‑3 hepatocytes accumulate labile iron due to impaired ferroportin export, which amplifies lipid peroxidation and triggers ferroptotic senescence. This senescent phenotype spreads via extracellular vesicle‑mediated transfer of oxidized lipids and mitochondrial DNA, causing paracrine aging in distant organs such as pancreas, kidney and heart, thereby linking hepatic zonation to systemic metabolic dysfunction.

Mechanistic basis

• Hypoxia‑iron axis: Low O2 in pericentral zones stabilizes HIF‑1α, which upregulates transferrin receptor (TFRC) and downregulates ferroportin (FPN1), increasing intracellular labile iron [https://royalsocietypublishing.org/doi/pdf/10.1098/rsif.2017.0443].
• Lipid overload: Reduced fatty acid oxidation and impaired PNPLA3‑mediated lipolysis cause lipid droplet accumulation, providing substrates for peroxidation [https://pmc.ncbi.nlm.nih.gov/articles/PMC8773141/].
• Ferroptosis trigger: Labile iron catalyzes Fenton reactions, generating lipid ROS that overwhelm GPX4 capacity, pushing hepatocytes toward ferroptotic damage [https://pmc.ncbi.nlm.nih.gov/articles/PMC12810195/].
• Senescence diversion: Sublethal ferroptotic stress activates p53‑p21 and DNA damage pathways, establishing the Aging Hepatocyte Gene Signature (AHGS) and a senescence‑associated secretory phenotype (SASP) [https://pmc.ncbi.nlm.nih.gov/articles/PMC12810195/].
• Paracrine spread: Senescent hepatocytes release extracellular vesicles enriched in oxidized phospholipids and mitochondrial DNA. Upon uptake by extra‑hepatic cells, these

We hypothesize that intermittent bouts of high-intensity exercise performed during the fasting window of time-restricted eating (TRE) create transient mTOR activation spikes that, when followed by prolonged mTOR suppression, push senescent cells into a metabolically vulnerable state characterized by NAD+ depletion and heightened reliance on BCL‑2 family survival proteins. This state increases the potency of senolytic agents such as dasatinib plus quercetin (D+Q) by inducing synthetic lethality through simultaneous disruption of anti‑apoptotic defenses and impaired DNA damage repair.

Mechanistic Basis

• Exercise acutely activates mTORC1 via mechanotransduction pathways (PI3K‑Akt‑STAT3) and increases ATP consumption, driving a short-lived anabolic burst that consumes NAD+ through increased PARP‑1 activity as cells attempt to repair exercise‑induced DNA damage (PMC8566556).
• The subsequent TRE‑mediated mTOR suppression (via reduced insulin/IGF‑1 signaling and AMPK activation) blocks the cell’s ability to replenish NAD+ through salvage pathways, because NAMPT expression is mTOR‑dependent (PMC7616065).
• Senescent cells already exhibit elevated PARP‑1 activity due to persistent DNA damage and a secretory phenotype that consumes NAD+ (10.1038/s41591-018-0092-9). The exercise‑induced NAD+ dip therefore pushes them below a critical threshold where SIRT1 activity falls, leading to hyperacetylation of p53 and impaired mitochondri

Hypothesis: Aging induces primary cilium shortening in stromal fibroblasts, which reduces SMO dwell time at the cilium tip and favors GLI2 proteolysis into repressor form, flattening the Shh gradient needed for stem cell activation. Senescence‑associated NF‑κB signaling further phosphorylates GLI2 at destabilizing sites, compounding repressor bias. We predict that pharmacological inhibition of GSK3β (which normally primes GLI2 for β‑TrCP‑mediated degradation) will shift the GLI2 processing balance toward the activator isoform, restoring a steep Shh gradient and regenerative output even when SMO ciliary trafficking is compromised. Crucially, this rescue should occur without increasing tumorigenic risk because GSK3β inhibition does not drive uncontrolled SMO activity; instead, it corrects downstream GLI processing that is uncoupled from oncogenic SMO mutations.

Testable predictions: 1. In young versus aged mouse muscle after cardiotoxin injury, immunofluorescence for acetylated tubulin and ARL13B will show a ~30% reduction in cilium length in aged PDGFRa+ fibroblasts (see et al., PMID:41673424). 2. FRAP of Smo‑GFP will reveal a decreased mobile fraction and faster recovery half‑time in aged fibroblasts, indicating shorter ciliary residency. 3. A Gli‑responsive luciferase reporter introduced into muscle explants will display a flattened spatial gradient (high proximal, low distal) in aged tissue; treatment with the GSK3β inhibitor CHIR99021 will steepen the gradient, whereas purmorphamine alone will not. 4. RNA‑seq of sorted fibroblasts will show increased expression

Hypothesis

We're proposing that antagonistic pleiotropy isn't a fixed trade‑but a tunable regulatory node where temporal patterning of signaling pathways determines whether early‑life benefits are coupled to late‑life costs. Specifically, pulsatile inhibition of mTORC1 during early adulthood can preserve its anabolic role for reproduction while preventing the chronic activation that drives senescence. If this decoupling works, lifespan can be extended without sacrificing fecundity.

Mechanistic Rationale

• Nutrient‑sensing circuits (mTOR, IGF‑1, AMPK) regulate both vitellogenesis and stress resistance. In C. elegans, the gene trl‑1 shifts resources to eggs by inhibiting vitellogenin, shortening life[[https://doi.org/10.1073/pnas.212031119]].
• It's known that chronic mTORC1 activity leads to lysosomal dysfunction and inflammaging, whereas transient mTORC1 pulses support protein synthesis needed for gametogenesis[[https://pmc.ncbi.nlm.nih.gov/articles/PMC9281621/]].
• Mathematical models of AP show that the strength of late‑life selection is negligible, allowing modifiers that alter the timing of pathway activity to persist if they boost early fitness[[https://augusta.elsevierpure.com/en/publications/is-antagonistic-pleiotropy-ubiquitous-in-aging-biology/]].

Testable Predictions

1. In C. elegans, administering rapamycin in short pulses (e.g., 4 h every 24 h) during the L4‑young adult window will increase brood size comparable to constitutive treatment while extending median lifespan >20 % relative to controls.
2. RNA‑seq of p

Hypothesis

Emodin, a natural anthraquinone from rhubarb, functions not as a senolytic but as a senomorphic agent that reinstates circadian clock amplitude in senescent cells, thereby dampening the senescence‑associated secretory phenotype (SASP) through coordinated inhibition of EGFR/MAPK signaling and NF‑κB‑driven transcription.

Mechanistic Rationale

1. Emodin inhibits EGFR/MAPK – demonstrated in macrophage polarization and cancer cell sensitization [39078513], [PMC6756157]; this pathway converges on the core clock by phosphorylating CRY1 and PER2, leading to their degradation and reduced BMAL1:CLOCK transcriptional activity.
2. Clock‑NF‑κB coupling – CLOCK:BMAL1 directly represses NF‑κB p65 transactivation and drives expression of autophagy genes (e.g., LC3, BECN1) that limit SASP [40900376]; conversely, NF‑κB activation suppresses BMAL1 transcription, creating a vicious loop in senescence.
3. Emodin‑mediated EGFR/MAPK blockade stabilizes CRY1/PER2, enhancing BMAL1:CLOCK binding to E‑box promoters of clock‑controlled genes (CCGs) including Nrf2, Sirt1, and Atg5. Increased BMAL1:CLOCK activity consequently:
   • Reinforces circadian oscillations of DNA‑repair and homeostatic genes.
   • Boosts autophagic flux, clearing damaged mitochondria and limiting cGAS‑STING activation.
   • Directly antagonizes NF‑κB nuclear translocation, reducing transcription of SASP components (IL‑6, IL‑8, MCP‑1, PAI‑1).
4. **Senom

Hypothesis

Intermittent mTORC1 activation in defined temporal patterns maintains epigenetic programs that specify cellular identity, whereas continuous suppression erodes these programs, leading to loss of tissue‑specific function despite lifespan extension.

Mechanistic Basis

mTORC1 activity drives S6K1‑dependent phosphorylation of ATP‑citrate lyase, increasing cytosolic acetyl‑CoA pools that fuel histone acetylation at lineage‑specific genes【https://pmc.ncbi.nlm.nih.gov/articles/PMC4845164/】. Pulses of mTORC1 signaling thus replenish acetyl‑CoA, sustaining H3K27ac marks that keep enhancers of hepatocyte, myocyte, and neuron programs in an open chromatin state. In contrast, prolonged mTORC1 inhibition lowers acetyl‑CoA, shifts the balance toward sirtuin‑mediated deacetylation, and promotes heterochromatin spread at identity loci, causing gradual dedifferentiation or fibrosis even as autophagy and stress resistance rise【https://pmc.ncbi.nlm.nih.gov/articles/PMC6611156/】.

Testable Predictions

1. Mice receiving daily 2‑hour mTORC1 activation pulses (via leucine bolus) on a rapamycin baseline will retain higher expression of tissue‑specific markers in liver and skeletal muscle after 18 months than mice on continuous rapamycin alone.
2. These pulsed mice will show improved functional readouts (grip strength, glucose tolerance, spontaneous activity) without sacrificing the lifespan extension seen with constant rapamycin.
3. Chromatin immunoprecipitation followed by sequencing will reveal elevated H3K27ac at promoters and enhancers of hepatocyte (Alb, Cyp2e1) and myo

Circadian disruption drives Zone 3 hepatocyte senescence by uncoupling mitophagy from metabolic demand, leading to mitochondrial damage, mtDNA‑cGAS‑STING activation and a SASP that fuels fibrosis. Restoring hepatic clock amplitude with a timed REV‑ERB agonist re‑synchronizes autophagy flux, while a senolytic clears the resulting senescent cells; together they should attenuate steatosis and fibrosis more effectively than either approach alone.

The core mechanism links the clock to mitochondrial quality control. REV‑ERBα peaks at ZT8‑10 and directly represses lipogenic genes, but it also activates transcription of autophagy regulators such as LC3 and PINK1. When REV‑ERBα rhythm is blunted—as occurs with high‑fat feeding or irregular eating—mitophagy falls, damaged mitochondria accumulate, and oxidized mtDNA escapes to the cytosol. Cytosolic mtDNA engages the cGAS‑STING pathway, triggering type I interferon signaling and a senescence‑associated secretory phenotype (SASP) marked by p16^Ink4a^ elevation and IL‑6 release. This SASP perpetuates inflammation, activates stellate cells, and accelerates pericentral fibrosis, consistent with the observation that severe Zone 3 steatosis predicts fibrosis progression with an odds ratio of 2.7.

We hypothesize that boosting NAD+‑SIRT1‑AMPK signaling—already shown to reduce lipogenesis—will further enhance REV‑ERBα‑dependent mitophagy, creating a feed‑forward loop that limits mitochondrial damage. Simultaneously, removing senescent hepatocytes with a senolytic (e.g., navitoclax) will blunt the SASP, breaking the fibrotic cascade. The comb

Hypothesis

Aging-associated ER stress upregulates NAF-1, which strengthens BCL-2 binding to Beclin-1 specifically at the ER membrane of macrophages. This heightened interaction suppresses autophagy, leading to mitochondrial ROS accumulation and NLRP3 inflammasome activation. Consequently, chronic inflammasome signaling drives age‑related tissue damage. Disrupting the NAF-1–BCL-2 interaction in myeloid cells should restore autophagy, dampen inflammasome activity, and extend healthspan.

Rationale

It's known that the BCL-2/Beclin-1 complex is a well‑characterized brake on autophagy that intensifies with age 23220384. Genetic release of Beclin-1 via the Becn1 F121A mutation improves autophagy, lifespan and organ function 29849149. NAF-1 has been shown to enhance BCL-2’s inhibitory function specifically at the ER 3304572. Aging triggers ER stress, which can increase NAF-1 expression 3901098. In macrophages, ER stress–induced ROS promotes NLRP3 inflammasome activation 23220384. Thus, NAF-1 may act as a stress‑dependent amplifier of the BCL-2/Beclin-1 brake, coupling ER stress to defective autophagy and inflammasome signaling.

Predictions

1. NAF-1 protein levels will be elevated in ER fractions of peritoneal macrophages from old (≥24 mo) mice compared with young (3 mo) mice.
2. Co‑immunoprecipitation will show increased BCL-2/Beclin-

Hypothesis

Senescent intestinal epithelial cells retain functional PXR and, when activated by indole‑3‑propionic acid (IPA), shift their senescence‑associated secretory phenotype (SASP) from proinflammatory to barrier‑enhancing. Rather than being mere sources of damage, these cells act as "hostage negotiators" that dampen neighboring epithelial proliferation and reinforce the mucosal barrier. Eliminating them with senolytics would remove this protective SASP, exacerbating barrier leakiness despite lowering senescent cell burden.

Mechanistic rationale

• PXR expression in senescence: PXR (NR1I2) is detectable in aged colonic epithelium and its activity correlates with increased expression of tight‑junction proteins. Senescent cells often exhibit altered nuclear receptor signaling; we propose that PXR remains ligand‑responsive in this state.
• IPA‑PXR axis suppresses NF‑κB: IPA inhibits TLR4/NF‑κB signaling, reducing TNF‑α and IL‑6. In senescent cells, NF‑κB drives the classic SASP (IL‑6, IL‑8, MMPs). PXR activation can compete for co‑activators (e.g., SRC‑1) and recruit corepressors (NCoR/SMRT) to NF‑κB target sites, thereby repressing SASP transcription.
• Cross‑talk with Nrf2: PXR activation induces Nrf2‑dependent antioxidant genes (HO‑1, NQO1). Nrf2 signaling is known to promote a SASP shift toward tissue‑repair factors (e.g., amphiregulin, TGF‑β1) while limiting metalloproteinases. Thus, IPA‑PXR‑Nrf2 cooperation could re‑program senescent gut cells to secrete barrier‑protective mediators.
• Autocrine reinforcement: Elevated claudin‑1, occludin, ZO‑1,

Hypothesis

Core idea

With advancing age, cytosolic cystatin B loses its inhibitory potency through oxidative modification of its active‑site cysteine, whereas lysosomal cystatin B remains functional due to the protective acidic lumen and lumenal chaperones. This selective loss creates a compartment‑specific defect: leaked cathepsins remain unchecked in the cytoplasm, damaging mitochondria and triggering neuroinflammation, while intra‑lysosomal proteolysis (including AGE clearance) stays intact.

Mechanistic rationale

• Cystatin B contains a reactive cysteine (Cys73) that forms disulfide bonds or S‑nitrosylation under oxidative stress, reducing its affinity for cathepsins B, L and D.
• The cytosol of aged neurons exhibits elevated ROS and RNS, favoring such modifications.
• Lysosomal lumen maintains a low pH (~4.5) and high concentration of lumenal thiol‑oxidizing enzymes that keep cystatin B in a reduced state, preserving its inhibitory loop.
• Oxidized cystatin B cannot form the tight canonically‑binding interaction with cathepsins, allowing cytosolic cathepsins to cleave substrates such as mitochondrial proteins or NLRP3, amplifying pyroptosis.
• Because lysosomal cathepsin activity depends on low pH rather than cystatin B, intra‑lysosomal degradation proceeds normally, explaining why cathepsin D over‑expression still improves AGE clearance.

Testable predictions

Chronic sleep loss accelerates colorectal cancer risk by disabling a nocturnal autophagy‑dependent quality‑control system for mismatch repair (MMR) proteins in colonic epithelium. During sleep, circadian‑driven expression of the lysosomal regulator TFEB peaks, coupling mTORC1 inhibition to the initiation of selective autophagy that targets oxidized or misfolded MMR complexes (e.g., MSH2, MLH1) for degradation. This process mirrors the brain’s glymphatic triage: only functional repair proteins are allowed to persist, while damaged subunits are cleared, preventing the accumulation of a mutator phenotype. Melatonin, whose secretion is maximal at night, amplifies TFEB activity and stabilizes the autophagosome‑lysosome fusion machinery, thereby coupling the circadian clock to proteostatic surveillance. When sleep is fragmented, TFEB activation blunts, autophagic flux falls, and damaged MMR proteins persist, impairing DNA mismatch correction and fostering field cancerization. This hypothesis is testable in aged murine colonic organoids subjected to controlled sleep‑fragmentation protocols. Predictions include: (1) reduced LC3‑II/I ratios and elevated p62 levels in organoids from sleep‑disrupted mice; (2) increased half‑life of MSH2 and MLH1 proteins measured by cycloheximide chase; (3) elevated microsatellite instability and point‑mutation burden after chronic disruption; (4) rescue of MMR fidelity by pharmacological TFEB activation (e.g., trehalose) or melatonin supplementation. Falsification would occur if sleep disruption fails to alter MMR protein turnover or mutation rates d

The beneficial versus harmful actions of senescent cells hinge on a metabolic checkpoint that governs their secretory phenotype. We hypothesize that elevated mitochondrial fission, mediated by Drp1 activation, pushes senescent fibroblasts into a chronic inflammatory SASP state, whereas promoting mitochondrial fusion sustains a transient, regeneration‑supporting SASP. This switch explains why young wound‑derived senescent cells express developmental programs that aid repair [https://doi.org/10.1101/2025.06.08.658533] while accumulated senescent cells in aging secrete factors that impair healing and drive fibrosis [https://doi.org/10.1007/s11357-022-00551-1].

In acute injury, transient senescence attracts immune cells for clearance and remodeling via a SASP rich in chemokines and growth factors [https://pmc.ncbi.nlm.nih.gov/articles/PMC12557303/]. Aging shifts the mitochondrial balance toward fission, increasing ROS production and NF‑κB signaling, which remodels the SASP toward IL‑6, IL‑1β, and TGF‑β dominance, thereby delaying healing and reinforcing paracrine senescence. Supporting this, transferring even a few senescent fibroblasts into young skin raises local senescence burden and impairs subsequent wound closure [https://doi.org/10.1007/s11357-022-00551-1], indicating that not all senescent cells are inherently reparative.

We propose that pharmacological modulation of mitochondrial dynamics can revert harmful senescent cells to a protective phenotype without eliminating them. Specifically, administering a Drp1 inhibitor (e.g., Mdivi‑1) or activating fusion promoters

Theme: AI Web3 + Healthcare + Science

Technical thesis: The next major healthcare infrastructure shift will come from the convergence of AI agents, interoperable data rails, and Web3 trust/settlement primitives. In this model, hospital operations, diagnostics support, treatment coordination, and research collaboration are orchestrated by specialized AI agents that can securely exchange context, verify provenance, and settle incentives across institutions.

Why this matters:

1. Healthcare systems are fragmented across EHR vendors, labs, insurers, and providers.
2. AI models are improving faster than clinical workflow integration.
3. Research reproducibility and data lineage remain difficult at scale.

Architecture

hypothesis: - AI Agent Layer: triage, care-path recommendation, prior-auth automation, discharge planning, trial matching.

• Interoperability Layer: standardized agent-to-agent contracts for referrals, results exchange, and decision handoff.
• Web3 Layer: verifiable audit trails, permissioned data attestations, tokenized incentive rails for outcomes and collaboration.

Hypothesis

Rapamycin extends lifespan by boosting autophagic flux and lysosomal biogenesis, but it does not repair the underlying defects that cause lysosomal membrane permeabilization (LMP) in aging. Overloading already‑compromised lysosomes with additional autophagic cargo could increase cathepsin leakage into the cytosol, thereby attenuating or even negating the putative longevity benefits. We hypothesize that the net effect of rapamycin on healthspan depends on the balance between induced proteolytic demand and the capacity of lysosomal membranes to resist permeabilization. When membrane‑stabilizing pathways are co‑activated, rapamycin’s autophagy upregulation should improve proteostasis without exacerbating cathepsin‑mediated damage; when they are not, rapamycin may accelerate cytosolic cathepsin activity and associated pathologies.

Mechanistic Rationale

1. Autophagy induction increases lysosomal load – Rapamycin upregulates LC3‑II conversion and autophagosome formation, delivering more long‑lived proteins and organelles to lysosomes for degradation [1]. In aged cells, lysosomal membranes are destabilized by Hsp70 carbonylation, ceramide/LysoPC accumulation, calpain activation, and v‑ATPase impairment [2].
2. Leaky lysosomes release cathepsins – Approximately one‑third of aged cortical neurons exhibit cytosolic cathepsin D due to LMP, lipofuscin buildup, and pH dysregulation [2]. Declining cystatin B further